AstraZeneca Research Development from 2010 to 2026
| AZN Stock | USD 208.45 4.47 2.19% |
Research Development | First Reported 1998-06-30 | Previous Quarter 3.7 B | Current Value 3.9 B | Quarterly Volatility 841.5 M |
Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 6 B, Interest Expense of 862.7 M or Total Revenue of 61.7 B, as well as many indicators such as Price To Sales Ratio of 4.65, Dividend Yield of 0.0218 or PTB Ratio of 5.61. AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
AstraZeneca | Research Development | Build AI portfolio with AstraZeneca Stock |
Evaluating AstraZeneca PLC's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into AstraZeneca PLC's fundamental strength.
Latest AstraZeneca PLC's Research Development Growth Pattern
Below is the plot of the Research Development of AstraZeneca PLC over the last few years. It is AstraZeneca PLC's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AstraZeneca PLC's overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
AstraZeneca Research Development Regression Statistics
| Arithmetic Mean | 7,687,509,550 | |
| Geometric Mean | 6,533,837,437 | |
| Coefficient Of Variation | 50.36 | |
| Mean Deviation | 3,184,299,141 | |
| Median | 5,991,000,000 | |
| Standard Deviation | 3,871,399,250 | |
| Sample Variance | 14987732.2T | |
| Range | 14.2B | |
| R-Value | 0.91 | |
| Mean Square Error | 2813183.8T | |
| R-Squared | 0.82 | |
| Slope | 695,937,013 | |
| Total Sum of Squares | 239803714.5T |
AstraZeneca Research Development History
About AstraZeneca PLC Financial Statements
AstraZeneca PLC investors utilize fundamental indicators, such as Research Development, to predict how AstraZeneca Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Research Development | 14.2 B | 14.9 B |
Pair Trading with AstraZeneca PLC
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.Moving together with AstraZeneca Stock
Moving against AstraZeneca Stock
| 0.67 | VRCA | Verrica Pharmaceuticals | PairCorr |
| 0.64 | 21P | Aurora Cannabis | PairCorr |
| 0.59 | BSFA | ANI Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of AstraZeneca PLC Correlation against competitors. To learn how to invest in AstraZeneca Stock, please use our How to Invest in AstraZeneca PLC guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Will Pharmaceuticals sector continue expanding? Could AstraZeneca diversify its offerings? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every AstraZeneca PLC data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.547 | Dividend Share 3.2 | Earnings Share 6.55 | Revenue Per Share | Quarterly Revenue Growth 0.041 |
The market value of AstraZeneca PLC is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that AstraZeneca PLC's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether AstraZeneca PLC represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, AstraZeneca PLC's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.